How can chronic liver disease affect liver cancer risk?
Last content review 2026-09-23
The short answer
Hepatocellular carcinoma risk rises with cirrhosis and with chronic hepatitis B, and it can also occur — less commonly — in advanced metabolic liver disease without cirrhosis. People with cirrhosis are usually offered regular surveillance because early detection changes what treatment is possible.
What is happening?
Long-standing injury, inflammation and regeneration cycles increase the chance of malignant change.
Surveillance typically involves periodic ultrasound, sometimes with a blood marker, at intervals decided by a clinician.
Why does this matter?
Surveillance is one of the clearest practical benefits of knowing your fibrosis stage.
It should be arranged and interpreted by a doctor, not self-scheduled based on internet reading.
What does the evidence say?
HCC surveillance in cirrhosis is recommended by AASLD and EASL guidance; specific intervals and eligibility are clinical decisions.
Key takeaway
Knowing your fibrosis stage is what makes appropriate cancer surveillance possible.
Sources & references
American Association for the Study of Liver Diseases
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023) · Clinical guideline
View original sourceEuropean Association for the Study of the Liver
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update (2021) · Clinical guideline
View original source
This page is general health education. It is not a diagnosis, and it cannot replace advice from your treating doctor. Never start or stop a prescribed medicine based on what you read here.
Related facts
Browse the LivRx FAQ →If this applies to you, a structured assessment with a qualified doctor is the appropriate next step.
Book an Assessment